$6.90▴ 1.47%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-1.05cash per $1 profit
Weak
Much of its reported profit is not backed by operating cash.
Valuation
74th pctvs its own history
Rich
Its valuation sits in the richer end of its own recent range.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
✦ The read
Abeona Therapeutics Inc. turns -105¢ of every reported profit-dollar into real cash. Much of its reported profit is not backed by operating cash. Its valuation sits in the richer end of its own recent range. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$1.07
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin817.6%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$9.12M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.